Home › Compare › SITIY vs ABBV
SITIY yields 10.41% · ABBV yields 3.06%● Live data
📍 SITIY pulled ahead of the other in Year 1
Combined, SITIY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SITIY + ABBV for your $10,000?
SITC International Holdings Company Limited, a shipping logistics company, provides integrated transportation and logistics solutions in Mainland China, Hong Kong, Taiwan, Japan, Southeast Asia, and internationally. It operates through two segments, Container Shipping and Logistics; and Dry Bulk and Others. The Container Shipping and Logistics segment offers container transportation, freight forwarding, shipping agency, and depot and warehousing services. The Dry Bulk and Others segment provides dry bulk vessel and land leasing, as well as air freight forwarding services. As of December 31, 2021, the company operated a fleet of 96 vessels with a total capacity of 143,115 TEU, including 68 self-owned vessels with a capacity of 103,663 TEU and 28 chartered vessels with a capacity of 39,452 TEU; and 5 dry bulk vessels with a total tonnage of 362,000 tons. It also offers container and vessel holding, and chartering; technology support; container maintenance; customs declaration; and multimodal transportation services. The company was founded in 1991 and is headquartered in Wan Chai, Hong Kong. SITC International Holdings Company Limited is a subsidiary of Resourceful Link Management Limited.
Full SITIY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.